Skip to main content
SpringerLink
Log in

The Evolution of Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck

The New Paradigm of Sequential Therapy

  • Chapter
Squamous Cell Head and Neck Cancer

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

Squamous cell carcinoma of the head and neck (HNSCC) represents 5% of newly diagnosed cancers in adult patients seen in the United States. Although HNSCC is a highly curable malignancy when diagnosed at an early stage, many patients present with advanced local-regional disease. Locally advanced disease can be separated into either intermediate (stage III; T3N0M0 or T1-3N1M0) or advanced (stage IV; T4N0-1M0 or T1-4N2-3M0) (1). Stage III patients are generally resectable, and although their prognosis is better a stage IV patients, the prognosis for all these patients, particularly those who are unresectable has remained poor (1–8). The potential for surgical resection, whether surgery is advised or not, defines a better prognosis than the presence of unresectable disease. Thus resectability, site, stage, and performance status are the major prognostic factors for patients with HNSCC. Standard therapy with surgery and/or radiotherapy can be associated with significant morbidity and functional disability, particularly when the tumor arises in the larynx, piriform sinus, or oropharynx (9). In addition, despite aggressive local therapy with surgery or radiotherapy, between 50 and 60% will develop locoregional recurrences, and 20 to 30% will develop distant metastases within 2 yr. Only 20 to 45% will remain disease free and alive at 3 yr.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fleming ID, Cooper JS, Henson DE, et al., eds. AJCC Cancer Staging Handbook, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 1998.

    Google Scholar 

  2. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324:1685–1689.

    Article  Google Scholar 

  3. Vermorken JB, Remenar E, Van Herpen C, et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). Proc ASCO 2004; 23:5508.

    Google Scholar 

  4. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del collo. J Natl Cancer Inst 1994; 86:265–272.

    Article  PubMed  CAS  Google Scholar 

  5. Forastiere A, Koch W, Trotti A, Sidransky D. Medical progress: head and neck cancer. N Engl J Med 2001; 345:1890–1900.

    Article  PubMed  CAS  Google Scholar 

  6. Adelstein D, Li Y, Adams G, et al. An Intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21:92–98.

    Article  PubMed  Google Scholar 

  7. Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002; 13:995–1006, 2002.

    Article  PubMed  CAS  Google Scholar 

  8. Posner MR. Head and Neck Cancer. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. Orlando, FL: WB Saunders Company, 2004: pp. 1195–2001.

    Google Scholar 

  9. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head and neck cancer. Int J Rad Oncol Biol Phys 2001; 50:1161–1171

    Article  CAS  Google Scholar 

  10. Kish J, Ensley J, Jacobs J, et al. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 1985; 56:2740–2744.

    Article  PubMed  CAS  Google Scholar 

  11. Kish J, Ensley J, Jacobs J, Binns P, Al-Sarraf M. Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer. Am J Clin Oncol 1988; 11:553–557.

    Article  PubMed  CAS  Google Scholar 

  12. Lefebvre J, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. J Natl Cancer Inst 1996; 88:890–898.

    Article  PubMed  CAS  Google Scholar 

  13. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced larynx cancer. The N Engl J Med 2003; 349:2091–2098.

    Article  CAS  Google Scholar 

  14. Calais G, Bardet E, Sire C, et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 Gortec Phase II trial. Int J Rad Oncol Biol Phys 2004; 58:161–166.

    Article  Google Scholar 

  15. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945–1952.

    Article  PubMed  CAS  Google Scholar 

  16. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91:2081–2086.

    Article  PubMed  CAS  Google Scholar 

  17. Depondt J, Gehanno P, Martin M, et al. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. Oncology 1993; 50:23–27.

    Article  PubMed  Google Scholar 

  18. Domenge C, Hill C, Lefebvre J, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer 2000; 83:1594–1598.

    Article  PubMed  CAS  Google Scholar 

  19. Pignon J, Bourhis J, Domenge C, Designe L, Group M-NC. Chemotherapy added to locoregional treatment for head and neck squamous-cell cancer: three meta-analysis of updated individual data. Lancet 2000; 355:949–955.

    PubMed  CAS  Google Scholar 

  20. Posner M, Colevas A, Tishler R. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Sem Oncol 2000; 27(Suppl G):13–24.

    CAS  Google Scholar 

  21. Haddad R, Wirth L, Posner M. The integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Exp Rev Anticancer Ther 2003; 3:331–338.

    Article  CAS  Google Scholar 

  22. Ensley J, Ahmed K, Kish J, Tapazoglou E, Al-Sarraf M. Salvage of patients with advanced squamous cell cancers of the head and neck (SCCHN) following induction chemotherapy failure using radiation and concurrent cisplatinum (CACP). In: Salmon S, ed. Adjuvant Therapy of Cancer VI, Philadelphia: WB Saunders, 1990: pp. 92–100:pp

    Google Scholar 

  23. Rooney M, Kish J, Jacobs J, et al. Improved complete response rate and survival in advanced head and neck cancer. Cancer 1985; 55:1123–1128.

    Article  PubMed  CAS  Google Scholar 

  24. Kish J, Weaver A, Jacobs J, Cummings G, Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and desseminated epidermoid cancer of the head and neck. Cancer 1984; 53:1819–1824.

    Article  PubMed  CAS  Google Scholar 

  25. Al-Kourainy K, Kish J, Ensley J, et al. Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 1987; 59:233–238.

    Article  PubMed  CAS  Google Scholar 

  26. Jacobs C, Goffinet D, Goffinet L, Kohler M, Fee W. Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 1987; 60:1178–1183.

    Article  PubMed  CAS  Google Scholar 

  27. De Andres L, Brunet J, Lopez-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and flourouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995; 13:1493–1500.

    PubMed  Google Scholar 

  28. Forastiere A, Metch B, Schuller D, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10:1245–1251.

    PubMed  CAS  Google Scholar 

  29. Clavel M, Vermorken J, Cognetti F, et al. Randomized comparison of cisplatin. methotrexate, bleomycin, and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus csiplatin (C), in recurrent or metastatic squamous cell carcinoma of the head and neck. A Phase III stduy of the EORTC head and neck cancer cooperative group. Ann Oncol 1994; 5:521–526.

    PubMed  CAS  Google Scholar 

  30. LHNOG. A phase III randomized trial of cisplatin, methotrexate, cisplatin + methotrexate and cisplatin + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 1990; 61:311–315.

    Google Scholar 

  31. Murphy B, Li Y, Cella D, Karnad A, Hussain M, Forastiere A. Phase iii study comparing cisplatin (C) and 5-flurouracil (F) versus cisplatin and paclitaxel (T) in metstatic/recurrent head and neck cancer (MHNC). Proc Am Soc Clin Oncol 2001; 20.

    Google Scholar 

  32. Paredes J, Hong W, Felder T, et al. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocabramate in recurrent and/or metastatic squamous cell cancer of the head and neck. J Clin Oncol 1988; 6:955–962.

    PubMed  CAS  Google Scholar 

  33. Schrijvers D, Johnson J, Jimenez U, et al. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 1998; 16:1054–1059.

    PubMed  CAS  Google Scholar 

  34. Jacobs C, Lyman G, Velez-Garcia E, et al. A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10:257–263.

    PubMed  CAS  Google Scholar 

  35. Takimoto C, Rowinsky E. Dose-intense paclitaxel: deja vu all over again? J Clin Oncol 2003; 21:2810–2814.

    Article  PubMed  CAS  Google Scholar 

  36. Kotelnikov V, Coon J IV, Haleem A, et al. Cell kinetics of head and neck cancer. Clin Cancer Res 1995; 1:527–537.

    PubMed  CAS  Google Scholar 

  37. Lefebvre J, Chevalier D, Luboinski B, et al. Is laryngeal preservation with induction chemotherapy safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891. Proc ASCO 2004; 23:5531.

    Google Scholar 

  38. Richard J, Sancho-Garnier H, Pessey J, et al. Randomized trial of induction chemotherapy in larynx cancer. Oral Oncol 1998; 34:224–228.

    Article  PubMed  CAS  Google Scholar 

  39. Zorat P, Loreggian L, Paccagnella A, et al. Randomized phase III trial of neoadjuvant chemotherapy (CT) in head and neck (H&N) cancer patients: an update based on 10 years’ follow up. Proc ASCO 2004; 23:5532.

    Google Scholar 

  40. Spaulding M, Fischer S, Wolf, G. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol 1994; 12:1592–1599.

    PubMed  CAS  Google Scholar 

  41. Clark J, Busse P, Norris C, et al. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 1997; 15:3100–3110.

    PubMed  CAS  Google Scholar 

  42. Clark JI, Hofmeister C, Choudhury A, et al. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer 2001; 92:2334–2340.

    Article  PubMed  CAS  Google Scholar 

  43. Janinis J, Papadakou M, Panagos G, et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 2001; 24:227–231.

    Article  PubMed  CAS  Google Scholar 

  44. Posner M, Glisson B, Frenette G, et al. A multi-center phase I-II trial of docetaxel, cisplatinum, and 5-fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001; 19:1096–1104.

    PubMed  CAS  Google Scholar 

  45. Schrijvers D, Van Herpen C, Kerger J, et al. Docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol 2004; 15:638–645.

    Article  PubMed  CAS  Google Scholar 

  46. Hitt R, Lopez-Pousa A, Rodriguez M, et al. Phase III study comparing cisplatin (P) & 5-fluoruracil (F) versus P, F and paclitaxel (T) as induction therapy in locally advanced head and neck cancer (LAHNC). Proc ASCO 2003; 22:496.

    Google Scholar 

  47. Colevas AD, Norris CM, Tishler RB, et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 2002; 25:153–159.

    Article  PubMed  CAS  Google Scholar 

  48. Shin DM, Glisson BS, Khuri FR, et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002; 95:322–330.

    Article  PubMed  CAS  Google Scholar 

  49. Haddad R, Norris C, Sulivan C, et al. Docetaxel, cisplatin and 5-fluorouracil based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana-Farber Cancer Institute experience. Cancer 2003; 97:412–418.

    Article  PubMed  CAS  Google Scholar 

  50. Cooper J, Pajak TF, Forastiere A, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937–1944.

    Article  PubMed  Google Scholar 

  51. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania phase II trial. J Clin Oncol 2002; 20:3964–3971.

    Article  PubMed  Google Scholar 

  52. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003; 21:320–326.

    Article  PubMed  Google Scholar 

  53. Kies MS, Haraf DJ, Athanasiadis I, et al. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol 1998; 16:2715–2721.

    PubMed  CAS  Google Scholar 

  54. Hainsworth JD, Meluch AA, McClurkan S, et al. Induction paclitaxel, carboplatin and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 2002.

    Google Scholar 

  55. Cmelak A, Murphy BA, Burkey B, Douglas S, Netterville J. Induction chemotherapy (IC) followed by concurrent chemoradiation (CCR) for organ preservation (OP) in locally advanced squamous head and neck cancer (SHNC): results of a phase II trial. Proc ASCO 2003; 22.

    Google Scholar 

  56. Urba S, Wolf G, Bradford C, et al. Improved survival and decreased late salvage surgery using chemo-selection of patients for organ preservation in advanced laryngeal cancer. Proc ASCO 2003; 22:497.

    Google Scholar 

  57. Grazia M, Paccagnells A, D’Amanzo P, et al. Neoadjuvant docetaxel, cisplatin, 5-fluoruracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. Int J Rad Oncol Biol Phys 2004; 59:481–487.

    Article  CAS  Google Scholar 

  58. Mason K, Hunter N, Milas M, Abbruzzese J, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997; 12:2431–2438.

    Google Scholar 

  59. Milross C, Mason K, Hunter N, et al. Enhanced radioresponse of pacitaxel-sensitive and-resistant tumors in vivo. Eur J Cancer 1997; 8:1299–1308.

    Article  Google Scholar 

  60. Tishler RB, Norris CM, Haddad R, et al. A phase I/II trial of docetaxel and concomitant boost radiation therapy for patients with squamous cell cancer of the head and neck following induction chemotherapy. Proc ASCO 2003; 22:506.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Head and Neck Oncology Program, Dana-Farber Cancer Institute, Boston, MA

    Marshall R. Posner MD, Lori Wirth MD, Roy B. Tishler MD, Charles M. Norris MD & Robert I. Haddad MD

Authors
  1. Marshall R. Posner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lori Wirth MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roy B. Tishler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charles M. Norris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert I. Haddad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH

    David J. Adelstein MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Posner, M.R., Wirth, L., Tishler, R.B., Norris, C.M., Haddad, R.I. (2005). The Evolution of Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck. In: Adelstein, D.J. (eds) Squamous Cell Head and Neck Cancer. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59259-938-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-938-7_12

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-473-9

  • Online ISBN: 978-1-59259-938-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation